BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38622605)

  • 1. Interferon-γ-induced GBP1 is an inhibitor of human papillomavirus 18.
    Xu M; Lin MC; Li ZH
    BMC Womens Health; 2024 Apr; 24(1):240. PubMed ID: 38622605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger ribonucleic acid encoding interferon-inducible guanylate binding protein 1 is induced in human endometrium within the putative window of implantation.
    Kumar S; Li Q; Dua A; Ying YK; Bagchi MK; Bagchi IC
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2420-7. PubMed ID: 11397834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Risk Mucosal Human Papillomavirus 16 (HPV16) E6 Protein and Cutaneous HPV5 and HPV8 E6 Proteins Employ Distinct Strategies To Interfere with Interferon Regulatory Factor 3-Mediated Beta Interferon Expression.
    Poirson J; Suarez IP; Straub ML; Cousido-Siah A; Peixoto P; Hervouet E; Foster A; Mitschler A; Mukobo N; Chebaro Y; Garcin D; Recberlik S; Gaiddon C; Altschuh D; Nominé Y; Podjarny A; Trave G; Masson M
    J Virol; 2022 May; 96(10):e0187521. PubMed ID: 35475668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
    Farhat S; Nakagawa M; Moscicki AB
    Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IFN-gamma produced by human papilloma virus-18 E6-specific CD4+ T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions.
    Seresini S; Origoni M; Lillo F; Caputo L; Paganoni AM; Vantini S; Longhi R; Taccagni G; Ferrari A; Doglioni C; Secchi P; Protti MP
    J Immunol; 2007 Nov; 179(10):7176-83. PubMed ID: 17982110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Papillomavirus (HPV) 16/18 E6 Oncoprotein Expression in Infections with Single and Multiple Genotypes.
    Wu Z; Li TY; Jiang M; Yu L; Zhao J; Wang H; Zhang X; Chen W; Qiao Y
    Cancer Prev Res (Phila); 2019 Feb; 12(2):95-102. PubMed ID: 30606718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway.
    Vintermyr OK; Iversen O; Thoresen S; Quint W; Molijn A; de Souza S; Rosillon D; Holl K
    Gynecol Oncol; 2014 May; 133(2):159-66. PubMed ID: 24631451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
    Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
    Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guanylate-Binding Protein 1, an Interferon-Induced GTPase, Exerts an Antiviral Activity against Classical Swine Fever Virus Depending on Its GTPase Activity.
    Li LF; Yu J; Li Y; Wang J; Li S; Zhang L; Xia SL; Yang Q; Wang X; Yu S; Luo Y; Sun Y; Zhu Y; Munir M; Qiu HJ
    J Virol; 2016 May; 90(9):4412-4426. PubMed ID: 26889038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel competitive enzyme-linked immunosorbent assay for the detection of the high-risk Human Papillomavirus 18 E6 oncoprotein.
    Contreras NE; Roldán JS; Castillo DS
    PLoS One; 2023; 18(8):e0290088. PubMed ID: 37582106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions.
    Jendoubi-Ferchichi M; Satouri L; Ghoul F; Malek-Mellouli M; Derbel AM; Makni MK; Reziga H; Baba A; Zili M; Segondy M; Khelifa R
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3361-3366. PubMed ID: 30583341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6.
    Evans M; Borysiewicz LK; Evans AS; Rowe M; Jones M; Gileadi U; Cerundolo V; Man S
    J Immunol; 2001 Nov; 167(9):5420-8. PubMed ID: 11673561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
    de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
    Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
    Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
    Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Variability in the E6, E7, and L1 Genes of Human Papillomavirus Types 16 and 18 among Women in Saudi Arabia.
    Alsanea M; Alsaleh A; Obeid D; Alhadeq F; Alahideb B; Alhamlan F
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZER1 Contributes to the Carcinogenic Activity of High-Risk HPV E7 Proteins.
    Nouel J; White EA
    mBio; 2022 Dec; 13(6):e0203322. PubMed ID: 36346242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.